SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Lantus

SNY·Sanofi
BEARISH
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already on market since April 2000 (26+ years).
Why 3/10
Lantus is an already-approved, marketed drug with no pending PDUFA date, pivotal readout, or other hard binary catalyst scheduled. The next notable event is finalization of the October 2026 tentative antitrust settlement, but that is a legal/commercial outcome, not a regulatory binary. As a mature declining product within a large diversified pharma company, its share-price impact is limited.
Actionable Insight BEARISH

Lantus has no upcoming FDA catalyst; the next event to watch is the finalization of the October 2026 tentative antitrust settlement with US wholesalers, which could involve a cash payment. More broadly, watch Sanofi's quarterly earnings for continued erosion of Lantus revenue as biosimilars (Semglee, LANGLARA) gain pharmacy shelf share. The real value story at Sanofi has shifted to Dupixent and newer launches, not Lantus.

Price Chart

Loading chart...

Executive Summary

Lantus (insulin glargine) is Sanofi's long-acting basal insulin, first FDA-approved in April 2000. It generated roughly EUR 1.7 billion in 2025 revenue but is in structural decline as multiple interchangeable biosimilars (Semglee since 2021, LANGLARA since May 2026) erode market share. Sanofi recently reached a tentative settlement of US antitrust claims alleging improper patent listings to block competition. Lantus is a mature, declining cash-flow product within Sanofi's diversified portfolio; the company's growth is now driven by Dupixent, vaccines, and rare-disease drugs. There are no pending FDA catalysts for Lantus.

How It Works

Lantus is a long-acting insulin analog (insulin glargine) that provides a steady, 24-hour baseline level of insulin to control blood sugar in people with type 1 and type 2 diabetes. It is injected once daily under the skin and is designed to have no pronounced peak, mimicking the body's natural basal insulin release.

Trial Status

Lantus is a fully approved, commercially marketed product. No new pivotal trials are underway for the original formulation. Biosimilar competitors have completed their own clinical programs to gain FDA approval and interchangeability designations.

The Two-Sided Case

▲ Bull Case4
Lantus still generated roughly EUR 1.7 billion in 2025 revenue, making it a meaningful cash-flow contributor even in decline.
Supply shortages of Lantus SoloStar pens in mid-2026 suggest persistent demand, and some patients may switch back once supply normalizes.
Sanofi's diversified portfolio means Lantus's decline is manageable; Q3 2026 total company sales grew 14.3% at CER, driven by Dupixent and new launches, offsetting the Lantus erosion.
The October 2026 tentative antitrust settlement removes a long-running legal overhang, even if it involves a payment.
▼ Bear Case5
Biosimilar erosion is accelerating: Semglee (Mylan) was the first interchangeable biosimilar insulin approved in 2021, and LANGLARA (Lannett/Lanexa/Sunshine Lake) was approved as an interchangeable biosimilar in May 2026, directly substitutable at the pharmacy counter without prescriber intervention.
Lantus revenue fell to approximately EUR 1.7 billion in 2025 (Statista), a fraction of its peak, and analysts describe a 'Lantus cliff' as biosimilar adoption grows.
Sanofi reached a tentative antitrust settlement on October 28, 2026 to resolve wholesaler claims that it used improper patent listings to suppress Lantus competition, which could involve financial penalties or business practice changes.
Supply constraints: Sanofi reported intermittent supply of Lantus SoloStar pens in mid-2026 amid rising demand, potentially ceding further ground to competitors.
Lantus is a 26-year-old product; Sanofi's strategic focus and R&D investment have shifted to immunology (Dupixent), vaccines, and rare diseases, not diabetes.

Upcoming Catalysts

  • Finalization of the October 2026 tentative US antitrust settlement with drug wholesalers (financial terms not yet disclosed).
  • Continued quarterly revenue erosion as interchangeable biosimilars (LANGLARA, Semglee) gain pharmacy-level substitution share.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 8

Hover a chip for the title
1 reuters.com2 statista.com3 jdsupra.com4 beckershospitalreview.com5 pharmadossier.com6 msn.com7 raps.org8 wellhn.com